143 related articles for article (PubMed ID: 35848215)
1. Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study.
Dang J; Segaux L; Moktefi A; Stehlé T; Kharoubi M; El Karoui K; Rémy P; Grimbert P; Plante-Bordeneuve V; Guendouz S; Galat A; Mallet S; Oghina S; Chadha GDS; Zaroui A; Fanen P; Canoui-Poitrine F; Damy T; Audard V
Amyloid; 2023 Mar; 30(1):38-48. PubMed ID: 35848215
[TBL] [Abstract][Full Text] [Related]
2. Pathological spectrum of hereditary transthyretin renal amyloidosis and clinicopathologic correlation: a French observational study.
Dang J; Ferlicot S; Misrahi M; Mussini C; Kounis I; Rémy P; Samuel D; Planté-Bordeneuve V; Adams D; Funalot B; Snanoudj R; Damy T; Moktefi A; Audard V; Zaidan M
Nephrol Dial Transplant; 2023 Aug; 38(9):2019-2030. PubMed ID: 36646436
[TBL] [Abstract][Full Text] [Related]
3. Progressive Decline in Estimated GFR in Patients With Sickle Cell Disease: An Observational Cohort Study.
Derebail VK; Ciccone EJ; Zhou Q; Kilgore RR; Cai J; Ataga KI
Am J Kidney Dis; 2019 Jul; 74(1):47-55. PubMed ID: 30797615
[TBL] [Abstract][Full Text] [Related]
4. Associations Between Weight Loss, Kidney Function Decline, and Risk of ESRD in the Chronic Kidney Disease in Children (CKiD) Cohort Study.
Ku E; Kopple JD; McCulloch CE; Warady BA; Furth SL; Mak RH; Grimes BA; Mitsnefes M
Am J Kidney Dis; 2018 May; 71(5):648-656. PubMed ID: 29132947
[TBL] [Abstract][Full Text] [Related]
5. Trajectories of Kidney Function in Patients with ATTRv Treated with Gene Silencers.
Luigetti M; Guglielmino V; Romano A; Sciarrone MA; Vitali F; D'Ambrosio V; Ferraro PM
Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553503
[TBL] [Abstract][Full Text] [Related]
6. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
[TBL] [Abstract][Full Text] [Related]
7. Renal Involvement in Hereditary Transthyretin Amyloidosis: An Italian Single-Centre Experience.
Ferraro PM; D'Ambrosio V; Di Paolantonio A; Guglielmino V; Calabresi P; Sabatelli M; Luigetti M
Brain Sci; 2021 Jul; 11(8):. PubMed ID: 34439599
[TBL] [Abstract][Full Text] [Related]
8. Sex Differences in the Progression of CKD Among Older Patients: Pooled Analysis of 4 Cohort Studies.
Minutolo R; Gabbai FB; Chiodini P; Provenzano M; Borrelli S; Garofalo C; Bellizzi V; Russo D; Conte G; De Nicola L;
Am J Kidney Dis; 2020 Jan; 75(1):30-38. PubMed ID: 31409508
[TBL] [Abstract][Full Text] [Related]
9. An Exploratory Study of Cognitive Involvement in Hereditary Transthyretin Amyloidosis.
Durmuş H; Çakar A; Demirci H; Alaylioglu M; Gezen-Ak D; Dursun E; Gülşen Parman Y
Acta Neurol Scand; 2021 Dec; 144(6):640-646. PubMed ID: 34322872
[TBL] [Abstract][Full Text] [Related]
10. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.
Siddiqi OK; Mints YY; Berk JL; Connors L; Doros G; Gopal DM; Kataria S; Lohrmann G; Pipilas AR; Ruberg FL
Amyloid; 2022 Jun; 29(2):71-78. PubMed ID: 35083944
[TBL] [Abstract][Full Text] [Related]
11. Serum bicarbonate concentrations and kidney disease progression in community-living elders: the Health, Aging, and Body Composition (Health ABC) Study.
Goldenstein L; Driver TH; Fried LF; Rifkin DE; Patel KV; Yenchek RH; Harris TB; Kritchevsky SB; Newman AB; Sarnak MJ; Shlipak MG; Ix JH;
Am J Kidney Dis; 2014 Oct; 64(4):542-9. PubMed ID: 24953890
[TBL] [Abstract][Full Text] [Related]
12. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS.
Caponetti AG; Rapezzi C; Gagliardi C; Milandri A; Dispenzieri A; Kristen AV; Wixner J; Maurer MS; Garcia-Pavia P; Tournev I; Planté-Bordeneuve V; Chapman D; Amass L;
JACC Heart Fail; 2021 Oct; 9(10):736-746. PubMed ID: 34391735
[TBL] [Abstract][Full Text] [Related]
13. N-acteyl-ß-D-glucosaminidase and kidney injury molecule-1: New predictors for long-term progression of chronic kidney disease in patients with heart failure.
Jungbauer CG; Uecer E; Stadler S; Birner C; Buchner S; Maier LS; Luchner A
Nephrology (Carlton); 2016 Jun; 21(6):490-8. PubMed ID: 26422793
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
15. Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting.
Kaboré NF; Poda A; Zoungrana J; Da O; Ciaffi L; Semdé A; Yaméogo I; Sawadogo AB; Delaporte E; Meda N; Limou S; Cournil A
BMC Nephrol; 2019 May; 20(1):155. PubMed ID: 31064340
[TBL] [Abstract][Full Text] [Related]
16. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.
Koye DN; Magliano DJ; Reid CM; Jepson C; Feldman HI; Herman WH; Shaw JE
Am J Kidney Dis; 2018 Nov; 72(5):653-661. PubMed ID: 29784612
[TBL] [Abstract][Full Text] [Related]
17. Association between hearing loss and hereditary ATTR amyloidosis.
Bartier S; Bodez D; Kharoubi M; Guellich A; Canouï-Poitrine F; Chatelin V; Coste A; Damy T; Béquignon E
Amyloid; 2019 Dec; 26(4):234-242. PubMed ID: 31502881
[No Abstract] [Full Text] [Related]
18. Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study.
Albenque G; Bézard M; Kharoubi M; Odouard S; Lunati A; Poullot E; Zaroui A; Teiger E; Hittinger L; Audard V; El Karoui K; Funalot B; Fanen P; Damy T; Oghina S
Amyloid; 2023 Dec; 30(4):407-415. PubMed ID: 37377439
[TBL] [Abstract][Full Text] [Related]
19. Urinary uromodulin independently predicts end-stage renal disease and rapid kidney function decline in a cohort of chronic kidney disease patients.
Steubl D; Block M; Herbst V; Nockher WA; Schlumberger W; Kemmner S; Bachmann Q; Angermann S; Wen M; Heemann U; Renders L; Garimella PS; Scherberich J
Medicine (Baltimore); 2019 May; 98(21):e15808. PubMed ID: 31124979
[TBL] [Abstract][Full Text] [Related]
20. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
